Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Paradigm to seek TGA nod after successful trial; EMVision uses AI simulation
News
Top 10 at 11: Juicy berries and autonomous cop drones got the market jingling this morning
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Health & Biotech
ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US
News
Market Highlights: ASX to fall; debt ceiling vote passed but traders fear it may cause a recession
Health & Biotech
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene
Health & Biotech
The chances of Phase 3 success, and the ASX health stocks that are close to a home run
Escrow Watch
Escrow Watch: Lithium junior Patriot Lithium ready to release shares in February
Health & Biotech
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
News
Closing Bell: When life gives you lemons, draw monkeys on ‘em and sell ’em to Bieber
Health & Biotech
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Health & Biotech
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
Experts
CRITERION: Gains without pains? Maybe tackle these sporting injury stocks instead
News
ASX Small Caps Lunch Wrap: Who’s reeling from a head knock this morning?
Health & Biotech
ASX Health Stocks: Mesoblast raise signals potential comeback for biotechs
News